GWP42006

DRUG4 trials

Sponsors

Jazz Pharmaceuticals

Conditions

Autism Spectrum DisorderEpilepsyFocal Seizures

Phase 1

A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects

CompletedNCT01918735

Jazz PharmaceuticalsEpilepsy

Start: 2013-08-31End: 2013-12-31Updated: 2022-12-20

Phase 2

A Study of GWP42006 in People With Focal Seizures - Part B

CompletedNCT02365610

Jazz PharmaceuticalsEpilepsy, Focal Seizures

Start: 2016-03-31End: 2017-09-30Updated: 2022-12-20

A Study of GWP42006 in People With Focal Seizures - Part A

CompletedNCT02369471

Jazz PharmaceuticalsEpilepsy, Focal Seizures

Start: 2015-03-31End: 2015-11-30Updated: 2022-12-20

Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder

TerminatedNCT03849456

Jazz PharmaceuticalsAutism Spectrum Disorder

Start: 2020-01-07End: 2020-05-26Updated: 2022-09-02

Related Papers

A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures

Cannabis and Cannabinoid Research2021-02-1724 citations